Pentoxifylline (oral 400 mg thrice daily) plus meglumine antimoniate (IMMA) (20 mg/ kg /day for 20 days) vs IMMA plus placebo
Recurrence ‐ not measured · People with American cutaneous leishmaniasis
The review found no eligible studies for this question.
1 finding from 1 review
- Interventions for American cutaneous and mucocutaneous leishmaniasis 2020 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found